Mikhail Blagosklonny is an editor, a professor, and a pre-eminent researcher in molecular and cell biology, as well as clinical studies. His proficiency in cancer and aging has earned him a role in the Roswell Park Cancer Institute in New York in 2009 as a lecturer on oncology topics. He holds a master’s degree in Internal Medicine from the First Pavlov State Medical University in St. Petersburg as well as a Ph.D. in Cardiology and Experimental Medicine.
Mikhail served at New York Medical College in Valhalla, New York from 2002 as an associate professor of medicine. He later worked at Ordway Research Institute as a senior scientist until he joined Roswell Park Cancer Institute on April 15, 2009. Roswell Cancer Institute allows experts to share ideas and various ways to control cancer. Mikhail’s in-depth knowledge on cancer has been useful at the institution, which has been harnessing the modern technologies to monitor the growth of tumors in lab animals.
Mikhail also holds various editorial positions in different journals, including the chief editor for Cell Cycle journals as well as biology and therapy associate editor. He sits on the editorial board for Cell Death and Differentiation. Mikhail is also a co-founder and editor in chief for Oncoscience, Oncotarget, and Aging. Read more on templeofthecave.com
Use of Rapamycin in Aging and Cancer
Mikhail Blagosklonny has interests in developing effective cancer therapies and mechanisms of aging. The primary goal of his research lies in developing therapies that would destroy cancer cells while at the same time protecting the healthy ones. His research directs to the potential role of TOR Signaling in cancer and aging. He suggests the use of rapamycin in slowing down the aging process and age-related illnesses. He goes further to indicate that the drug could be used to prolong the life of cancer patients in addition to its usual role in boosting the immunity and reducing multiplication of cancer cells. This research has now earned him recognition as a rapamycin advocate.
His Other Works
Mikhail has published over 300 book chapters, articles, and reviews on aging, chemotherapeutic engineering, oncology, and cell cyclotherapy. His informative publications have earned him an h0-index of 83 as well as over 25,000 citations by various researchers globally. Mikhail Blagosklonny is also an associate editor of the American Journal of Pathology, International Journal for Cancer, and PLUS ONE. He has also done research in various areas such as clinical investigations, mitosis cell cycle, tumor suppressors, apoptosis, and oncogenesis.
Read more: http://www.aging-us.com/article/100591/text